Assetmark Inc. boosted its position in shares of Masimo Co. (NASDAQ:MASI – Free Report) by 44.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,275 shares of the medical equipment provider’s stock after acquiring an additional 3,158 shares during the period. Assetmark Inc.’s holdings in Masimo were worth $1,896,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Masimo by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock valued at $695,050,000 after purchasing an additional 71,918 shares during the period. State Street Corp raised its stake in shares of Masimo by 1.6% in the 1st quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider’s stock valued at $251,928,000 after buying an additional 27,261 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Masimo by 92.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 856,664 shares of the medical equipment provider’s stock worth $111,940,000 after acquiring an additional 410,793 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Masimo by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 703,196 shares of the medical equipment provider’s stock worth $103,920,000 after acquiring an additional 31,667 shares during the period. Finally, Schroder Investment Management Group boosted its position in shares of Masimo by 44.9% during the 4th quarter. Schroder Investment Management Group now owns 577,277 shares of the medical equipment provider’s stock valued at $85,408,000 after acquiring an additional 178,753 shares in the last quarter. Institutional investors and hedge funds own 84.11% of the company’s stock.
Insider Activity at Masimo
In other news, CEO Joe E. Kiani acquired 6,365 shares of the company’s stock in a transaction on Thursday, May 25th. The stock was purchased at an average cost of $157.16 per share, with a total value of $1,000,323.40. Following the acquisition, the chief executive officer now owns 366,055 shares of the company’s stock, valued at approximately $57,529,203.80. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 9.70% of the stock is owned by company insiders.
Masimo Trading Down 2.4 %
Masimo (NASDAQ:MASI – Get Free Report) last posted its quarterly earnings data on Tuesday, May 9th. The medical equipment provider reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.04. The firm had revenue of $565.00 million for the quarter, compared to the consensus estimate of $557.87 million. Masimo had a return on equity of 19.32% and a net margin of 5.16%. The business’s revenue for the quarter was up 85.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.93 EPS. As a group, equities analysts anticipate that Masimo Co. will post 4.43 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research firms recently issued reports on MASI. Stifel Nicolaus lowered shares of Masimo from a “buy” rating to a “hold” rating and dropped their price target for the stock from $205.00 to $120.00 in a research report on Tuesday, July 18th. Wells Fargo & Company decreased their price target on Masimo from $126.00 to $110.00 in a research note on Wednesday. StockNews.com began coverage on Masimo in a research note on Thursday, May 18th. They set a “hold” rating for the company. Needham & Company LLC reduced their target price on shares of Masimo from $207.00 to $136.00 and set a “buy” rating on the stock in a research note on Tuesday, July 18th. Finally, BTIG Research dropped their target price on shares of Masimo from $200.00 to $153.00 in a research report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and an average price target of $157.56.
View Our Latest Research Report on Masimo
Masimo Profile
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
See Also
- Five stocks we like better than Masimo
- Airline Stocks: What They Are and How to Invest
- 2 Tech Stocks to Buy and One to Avoid in August
- Space Investment: How to Invest in Space Exploration
- AI is Turning Things Up for Upwork
- How to Invest in Casino Stocks
- 5 Best Fintech Stocks to Buy Now
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.
